Fabre Kramer Re-Acquires Gepirone ER Rights From Organon

Fabre-Kramer Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, and Organon, the human healthcare business unit of Akzo Nobel , announced that they have reached an agreement under which Fabre-Kramer is re-acquiring all rights related to Gepirone ER, a once-daily product being developed for the treatment of depression.

()a href="http://www.biospace.com/news_story.cfm?StoryID=20354420&full=1" target="_blank">BioSpace